Results 71 to 80 of about 31,333 (185)
Anemia in Lymphoproliferative Disorders [PDF]
Cancer Control, 1998 The onset of anemia in patients with lymphoproliferative disorders can be attributed to various causes, including autoimmune hemolytic anemia, pure red cell aplasia, and anemia of chronic disease. A variety of interventions can provide benefit.
openaire +2 more sources
Vox Sanguinis, EarlyView.Abstract Background and Objectives The presence of warm autoantibodies (WAAs) complicates pre‐transfusion and compatibility testing. Despite attempts to provide antigen‐matched red blood cells (RBCs), the risk of alloimmunization remains. Rates of alloimmunization and indications for transfusion were reviewed to streamline testing and RBC provision ...
S. Hutspardol +8 more
wiley +1 more source
Pure Red Cell Aplasia and Lymphoproliferative Disorders: An Infrequent Association
The Scientific World Journal, 2012 Pure red cell aplasia (PRCA) is a rare bone marrow failure syndrome defined by a progressive normocytic anaemia and reticulocytopenia without leukocytopenia and thrombocytopenia.
Efthymia Vlachaki +5 more
doaj +1 more source
Hematological Oncology, Volume 44, Issue 2, March 2026.ABSTRACT Post‐transplant lymphoproliferative disorder (PTLD) is a rare, dreaded complication of organ transplantation with major clinical challenges. We conducted a nationwide population‐based study of all solid organ transplant (SOT) recipients (n = 6555), both adults and children, over a 30‐year period in Finland.
Terhi K. Friman +11 more
wiley +1 more source
Diabetic Medicine, Volume 43, Issue 3, March 2026.Abstract Aims To explore UK key‐opinion leader perspectives on the future role of stem cell‐derived islets (sc‐islets) in islet transplantation for people with type 1 diabetes (T1D). Methods Four UK‐based key‐opinion leaders evaluated current limitations of donor islet transplantation and reviewed emerging evidence, clinical pathways and logistical ...
Thomas Strakosch, Shareen Forbes
wiley +1 more source
Haematologica, 2007 Background and Objectives The elective treatment of patients with post-transplant lymphoproliferative disorders is controversial. The purpose of this trial was to evaluate the efficacy of treatment with extended doses of rituximab adapted to the response
Eva González-Barca +11 more
doaj +1 more source
Veterinary and Comparative Oncology, Volume 24, Issue 1, Page 41-50, March 2026.ABSTRACT Alkaline phosphatase (ALP) enzymatic activity has been proposed as a marker for distinguishing canine acute leukaemia (AL) subtypes (i.e., myeloid vs. lymphoid). However, ALP enzymatic activity has not been fully evaluated in CD34+ AL. Determine whether ALP enzymatic activity can differentiate CD34+ AL subtypes in dogs and distinguish CD34+ AL
Megan Aalto +7 more
wiley +1 more source
Sulfasalazine-Induced Epstein–Barr Virus-Positive Mucocutaneous Ulcer
Case Reports in HematologyEpstein–Barr virus (EBV) may cause a wide spectrum of symptomatology in humans ranging from asymptomatic upper respiratory tract infection to infectious mononucleosis and in more severe cases lymphoproliferative disorders or hemophagocytic ...
Cedric Stabel +3 more
doaj +1 more source
Clinical, genetic, and familial features of POT1 tumor predisposition syndrome
Cancer, Volume 132, Issue 4, 15 February 2026.Abstract Background Protection of telomere 1 (POT1) tumor predisposition syndrome (POT1‐TPD) is a hereditary leukemia syndrome that is identified in ∼5% of patients with chronic lymphocytic leukemia (CLL) and is characterized by a predisposition to other cancers, including gliomas, melanomas, and angiosarcomas.
Courtney D. DiNardo +13 more
wiley +1 more source
Advanced Science, Volume 13, Issue 9, 13 February 2026.This study finds that CD8⁺ TSCM cells exhibit superior self‐renewal, differentiation, and antiviral activity. Transcriptome and epigenome analyses highlight MAPK cascade regulation in TSCM cells. In vivo, virus‐specific TSCM cells show enhanced persistence and tumor protection.
Xun‐Hong Cao +13 more
wiley +1 more source